Quantcast

Latest Sinai Stories

2013-08-12 09:51:39

The multipronged approach directly attacks cancer cells, blocking the growth of cancer-supporting blood vessels and stimulating an antitumor immune response A unique nanoscale drug that can carry a variety of weapons and sneak into cancer cells to break them down from the inside has a new component: a protein that stimulates the immune system to attack HER2-positive breast cancer cells. The research team developing the drug – led by scientists at the Nanomedicine Research Center, part...

2013-07-24 23:02:44

Mount Sinai and Emek Medical Center in Israel Announce an Agreement to Collaborate on Future Projects New York, NY (PRWEB) July 24, 2013 Childhood obesity rates in Israel are now similar to those in the United States, according to a new study conducted by researchers at Mount Sinai Global Health (http://icahn.mssm.edu/research/programs/mount-sinai-global-health), a program at the Icahn School of Medicine at Mount Sinai, and Clalit Health Services in Israel...

2013-05-31 23:16:33

Results of a study on 10 years of experience retraining anesthesiologists in a simulation program at the Icahn School of Medicine at Mount Sinai reveal that 70 percent of participants returned to active practice within one year of completing the program. (PRWEB) May 31, 2013 Results of a study on 10 years of experience retraining anesthesiologists in a simulation program at the Icahn School of Medicine at Mount Sinai reveal that 70 percent of participants returned to active practice within...

2013-05-20 11:17:12

Drug associated with rapid antidepressant effect in largest clinical trial to date Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai. The antidepressant benefits of ketamine were seen within 24 hours, whereas traditional antidepressants can take days or weeks to demonstrate a...

2013-05-10 23:02:34

Mount Sinai´s International Center for Health Outcomes and Innovation Research (InCHOIR) is the data-coordinating center for the trial. New York, nY (PRWEB) May 10, 2013 Today the National Institute of Neurological Disorders and Stroke (NINDS) announced that “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) has stopped enrolling patients because of higher than expected event rates in the interventional therapy arm. The International Center for...

2013-05-09 23:21:42

℠Cureatr´ App Developed by Mount Sinai Hospital Resident Dr. Joseph Mayer New York (PRWEB) May 09, 2013 The Mount Sinai Medical Center has adopted an enterprise-grade mobile care-coordination mobile app called Cureatr, which was designed by a resident at the Mount Sinai Hospital, Joseph Mayer, MD. Mount Sinai has signed a multi-year contract to roll out the app to Mount Sinai clinicians. “Mount Sinai is the first major academic medical center to adopt Cureatr,” said...

2013-05-07 23:23:32

Mount Sinai Researcher Estimates that Lead Exposure Could Cause Mental Retardation in 6 in 1,000 Children Living Near the Sites New York, NY (PRWEB) May 07, 2013 Children living near toxic waste sites in lower and middle income countries such as India, Philippines and Indonesia may experience higher blood lead levels, resulting in a loss of IQ points and a higher incidence of mental retardation, according to a study presented today by Kevin Chatham-Stephens, MD, Pediatric Environmental...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related